Native Americans in Iowa 2006 (American Indian heritage month: Native Americans in Iowa, November 2006)

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2007

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2008

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2009

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2010

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2011

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2012

Demographic profile of the Native American population in Iowa compiled from Census statistics.

Native Americans in Iowa 2015

Demographic profile of the Native American population in Iowa compiled from Census statistics.

IEDA 2013 Annual Report Displayed by Status (January 2014)

Each year, IEDA’s contract compliance team compiles a report of the status of each business project awarded or under contract. The FY14 annual report measures status and progress of projects awarded since 2003 and tracked by the compliance team. Within this version of the report, the projects are grouped by status. Within this version of the report, the projects are first grouped by the status.

Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.

Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other newer agents. Here we review the mechanisms of action, pharmacological properties and side effects of parenteral anticoagulants used in the management of coronary heart disease treated with or without percutaneous coronary interventions, cardioversion for atrial fibrillation, and prosthetic heart valves and valve repair. Using an evidence-based approach, we describe the results of completed clinical trials, highlight ongoing research with currently available agents, and recommend therapeutic options for specific heart diseases.

Status of the Iowa Workforce and Economy, September 2015

Iowa Workforce Development's newsletter.